Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

BACKGROUND: Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment, is desirable for patients. OBJECTIVES: This study...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Pharmacokinet
Auteurs principaux: Yin, Anyue, Ettaieb, Madeleine H. T., Swen, Jesse J., van Deun, Liselotte, Kerkhofs, Thomas M. A., van der Straaten, Robert J. H. M., Corssmit, Eleonora P. M., Gelderblom, Hans, Kerstens, Michiel N., Feelders, Richard A., Eekhoff, Marelise, Timmers, Henri J. L. M., D’Avolio, Antonio, Cusato, Jessica, Guchelaar, Henk-Jan, Haak, Harm R., Moes, Dirk Jan A. R.
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2020
Sujets:
Original Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809008/
https://ncbi.nlm.nih.gov/pubmed/32607875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00913-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires